New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show
Oncology/Hematology > > Leukemia-- Results of FELIX research study supported obecabtagene autoleucel's current FDA approval
by Mike Bassett, Staff Writer, MedPage Today November 27, 2024
Usage of the anti-CD19 CAR T-cell treatment obecabtagene autoleucel (obe-cel; Aucatzyl) led to resilient remissions amongst clients with fallen back or refractory B-cell intense lymphoblastic leukemia (ALL), according to arise from the stage Ib/II FELIX trial.
In an associate of 94 clients with morphologic illness, total remission took place in 77% of those who got a minimum of one infusion of obe-cel, with total remission ...